{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:57:33Z","timestamp":1777510653891,"version":"3.51.4"},"reference-count":86,"publisher":"Informa UK Limited","issue":"1","funder":[{"name":"Novartis and UCB"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Immunotherapy"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.2217\/imt-2020-0225","type":"journal-article","created":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T07:10:05Z","timestamp":1604992205000},"page":"19-33","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":7,"title":["Ixekizumab in the Treatment of Psoriatic Arthritis"],"prefix":"10.1080","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1009-8518","authenticated-orcid":false,"given":"Eric","family":"Lespessailles","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Regional Hospital of Orleans, 45067\u00a0Orleans, France"},{"name":"University of Orleans, EA 4708\u00a0\u2013 I3MTO Laboratory, 45067Orleans, France"},{"name":"Translational Medicine Research Platform, PRIMMO, Regional Hospital of Orleans, 45067Orleans, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4589-7731","authenticated-orcid":false,"given":"Hechmi","family":"Toumi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Regional Hospital of Orleans, 45067\u00a0Orleans, France"},{"name":"University of Orleans, EA 4708\u00a0\u2013 I3MTO Laboratory, 45067Orleans, France"},{"name":"Translational Medicine Research Platform, PRIMMO, Regional Hospital of Orleans, 45067Orleans, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2020,11,9]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-197409000-00002"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.339"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.11.013"},{"issue":"3","key":"e_1_3_3_7_1","first-page":"191","article-title":"Psoriatic arthritis - update on pathophysiology, assessment, and management","volume":"68","author":"Mease PJ","year":"2010","unstructured":"Mease PJ . Psoriatic arthritis - update on pathophysiology, assessment, and management. Bull. NYU Hosp. Jt Dis.68(3), 191\u2013198 (2010).","journal-title":"Bull. NYU Hosp. Jt Dis."},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.029207"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/03009740802609558"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-007-0073-3"},{"issue":"8","key":"e_1_3_3_11_1","first-page":"S216","article-title":"Psoriasis and psoriatic arthritis overview","volume":"22","author":"Menter A","year":"2016","unstructured":"Menter A . Psoriasis and psoriatic arthritis overview. Am. J. Manag. Care22(Suppl. 8), S216\u2013S224 (2016).","journal-title":"Am. J. Manag. Care"},{"issue":"2","key":"e_1_3_3_12_1","first-page":"ii14","article-title":"Psoriatic arthritis: epidemiology, clinical features, course, and outcome","volume":"64","author":"Gladman DD","year":"2005","unstructured":"Gladman DD . Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann. Rheum. Dis.64(Suppl. 2), ii14\u2013ii17 (2005).","journal-title":"Ann. Rheum. Dis."},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-016-0029-z"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000012807"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199806)41:6<1103::AID-ART18>3.0.CO;2-N"},{"issue":"2","key":"e_1_3_3_16_1","first-page":"ii26","article-title":"Immunopathology of psoriasis and psoriatic arthritis","volume":"64","author":"Veale DJ","year":"2005","unstructured":"Veale DJ . Immunopathology of psoriasis and psoriatic arthritis. Ann. Rheum. Dis.64(Suppl. 2), ii26\u2013ii29 (2005).","journal-title":"Ann. Rheum. Dis."},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2007.10.007"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0001-7310(14)70014-6"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.404"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23655"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1700596"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.188"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215356"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39573"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217159"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes001"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32483-8"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615975"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202959"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60725-4"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60726-6"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60594-2"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204655"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208337"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40728"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.38376"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.33396"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-209055"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61134-5"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-205056"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri3707"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0707449"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S100940"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.04.024"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109997"},{"key":"e_1_3_3_46_1","unstructured":"Human medicine European public assessment report (EPAR)\n. Taltz. http:\/\/www.ema.europa.eu"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1268"},{"issue":"9","key":"e_1_3_3_48_1","first-page":"1","article-title":"Exposure response analyses to describe the relationship between ixekizumab concentrations and Acr responses in psoriatic arthritis patients [abstract]","volume":"70","author":"Ernest CI","year":"2018","unstructured":"Ernest CI , Velezde Mendizabal N , HuL. Exposure response analyses to describe the relationship between ixekizumab concentrations and Acr responses in psoriatic arthritis patients [abstract]. Arthritis Rheumatol.70(Suppl. 9), 1\u20133584 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.reprotox.2015.10.008"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209709"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31429-0"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1831-0"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170429"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key182"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez684"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key161"},{"issue":"4","key":"e_1_3_3_57_1","first-page":"566","article-title":"Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors: SPIRIT-P2 results to 52 weeks","volume":"37","author":"Kavanaugh A","year":"2019","unstructured":"Kavanaugh A , Marzo-OrtegaH , VenderRet al. Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors: SPIRIT-P2 results to 52 weeks. Clin. Exp. Rheumatol.37(4), 566\u2013574 (2019).","journal-title":"Clin. Exp. Rheumatol."},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41927-018-0030-y"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-215003"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.032268"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22379"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204902"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20335"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000567"},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000692"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215386"},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217372"},{"key":"e_1_3_3_68_1","unstructured":"The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP)\n. PRO-SPIRIT Study. www.encepp.eu\/encepp\/viewResource.htm?id=31175"},{"key":"e_1_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20627"},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201194"},{"key":"e_1_3_3_71_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21725"},{"key":"e_1_3_3_72_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130797"},{"key":"e_1_3_3_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61909-7"},{"key":"e_1_3_3_74_1","first-page":"keaa189","article-title":"Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials","author":"Genovese MC","year":"2020","unstructured":"Genovese MC , MyslerE , TomitaTet al. Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials. Rheumatologykeaa189 (2020).","journal-title":"Rheumatology"},{"key":"e_1_3_3_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.09.026"},{"key":"e_1_3_3_76_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23738"},{"key":"e_1_3_3_77_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-020-2099-0"},{"key":"e_1_3_3_78_1","doi-asserted-by":"publisher","DOI":"10.1097\/JDN.0000000000000497"},{"key":"e_1_3_3_79_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17604"},{"key":"e_1_3_3_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.02.074"},{"issue":"2","key":"e_1_3_3_81_1","first-page":"200","article-title":"Safety and tolerability of ixekizumab: integrated analysis of injection-site reactions from 11 clinical trials","volume":"17","author":"Shear NH","year":"2018","unstructured":"Shear NH , PaulC , BlauveltAet al. Safety and tolerability of ixekizumab: integrated analysis of injection-site reactions from 11 clinical trials. J. Drugs Dermatol.17(2), 200\u2013206 (2018).","journal-title":"J. Drugs Dermatol."},{"key":"e_1_3_3_82_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-017-0249-y"},{"key":"e_1_3_3_83_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2015.1027167"},{"issue":"2","key":"e_1_3_3_84_1","first-page":"182","article-title":"Hypertension and diabetes significantly enhance the risk of cardiovascular disease in patients with psoriatic arthritis","volume":"32","author":"Favarato MH","year":"2014","unstructured":"Favarato MH , MeaseP , Gon\u00e7alvesCR , Gon\u00e7alvesSaad C , Sampaio-BarrosPD , Goldenstein-SchainbergC. Hypertension and diabetes significantly enhance the risk of cardiovascular disease in patients with psoriatic arthritis. Clin. Exp. Rheumatol.32(2), 182\u2013187 (2014).","journal-title":"Clin. Exp. Rheumatol."},{"key":"e_1_3_3_85_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10774.x"},{"key":"e_1_3_3_86_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12350"},{"issue":"9","key":"e_1_3_3_87_1","first-page":"1","article-title":"Anti-drug antibodies, efficacy, and impact of concomitant methotrexate in ixekizumab-treated patients with psoriatic arthritis [abstract]","volume":"70","author":"Ritchlin C","year":"2018","unstructured":"Ritchlin C , MerolaJ , GellettA , LinC , MuramM. Anti-drug antibodies, efficacy, and impact of concomitant methotrexate in ixekizumab-treated patients with psoriatic arthritis [abstract]. Arthritis Rheumatol.70(Suppl. 9), 1\u20133584 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"e_1_3_3_88_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0612-475"}],"container-title":["Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/imt-2020-0225","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T15:00:57Z","timestamp":1715958057000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/imt-2020-0225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,9]]},"references-count":86,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["10.2217\/imt-2020-0225"],"URL":"https:\/\/doi.org\/10.2217\/imt-2020-0225","relation":{},"ISSN":["1750-743X","1750-7448"],"issn-type":[{"value":"1750-743X","type":"print"},{"value":"1750-7448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,9]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-08-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}